| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 13,430 | 16,030 | 14,320 | 13,940 | 14,160 |
| Sales Growth | -16.22% | +11.94% | +2.73% | -1.55% | -15.36% |
| Net Income | 36,330 | -1,460 | -3,710 | -1,760 | -27,350 |
| Net Income Growth | +2,588.36% | +60.65% | -110.80% | +93.56% | -46.26% |
Lensar Inc (LNSR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
LENSAR Inc. is a commercial-stage medical device company. It focuses on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. LENSAR Inc. is based in Orlando, Florida.
Fiscal Year End Date: 12/31